NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer-Reference-Cited by-同舟云学术

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

Published:2017-03-07 Issue:15 Volume:23 Page:4055-4065
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Ma Cynthia X.,Gao Feng,Luo Jingqin,Northfelt Donald W.,Goetz Matthew,Forero Andres,Hoog Jeremy,Naughton Michael,Ademuyiwa Foluso,Suresh Rama,Anderson Karen S.,Margenthaler Julie,Aft Rebecca,Hobday Timothy,Moynihan Timothy,Gillanders William,Cyr Amy,Eberlein Timothy J.,Hieken Tina,Krontiras Helen,Guo Zhanfang,Lee Michelle V.,Spies Nicholas C.,Skidmore Zachary L.,Griffith Obi L.,Griffith Malachi,Thomas Shana,Bumb Caroline,Vij Kiran,Bartlett Cynthia Huang,Koehler Maria,Al-Kateb Hussam,Sanati Souzan,Ellis Matthew J.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 253 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-09-12

2. Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study;2024-09-01

3. Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer;Current Treatment Options in Oncology;2024-08-15

4. The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer;Future Oncology;2024-07-29

5. Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer;Scientific Reports;2024-07-11